Elad Sharon and Colleagues: How a Common Trait Unfairly Excludes Black Patients from Cancer Trials
Elad Sharon, Associated Professor of Medicine at Dana-Farber, shared a post on X:
“Very proud of this effort led by one of our former Dana-Farber fellows, Lauren Merz, on the Duffy null phenotype. Thanks to JAMA Oncology for highlighting! Important to see that many otherwise healthy patients are unfairly being excluded because of an arbitrary number… the National Cancer Institute”
Quoting JAMA Oncology’s post:
“Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity.”
Title: Duffy Null–Associated Absolute Neutrophil Counts and Cancer Clinical Trial Eligibility
Authors: Lauren E. Merz, Yating Wang, Angel Cronin, Elad Sharon, Thomas P. Walsh, Stephen P. Hibbs, Christopher S. Lathan, Andrew Hantel
Read full article here.
Never miss hematology updates with Hemostasis Today.
-
Apr 8, 2026, 18:14Simon Fletcher: See The Unique Challenges PwH Face During Their Gene Therapy Journey
-
Apr 8, 2026, 17:56Hisam Siddiqi: Understanding Bone Marrow Trephine Morphology in MPNs
-
Apr 8, 2026, 17:46Mohamed Reda: Why Some Veins Decide to Take a ‘Detour’?
-
Apr 8, 2026, 17:39Managing Acquired Von Willebrand Syndrome in a Swine Polytrauma Model During ECLS – JTH
-
Apr 8, 2026, 17:04Heghine Khachatryan: Marfan vs LDS – Not All Aortopathies Are the Same
-
Apr 8, 2026, 17:00Frits Rosendaal Receives ISTH Grant Medal for Lifetime Contributions to Thrombosis and Hemostasis Field
-
Apr 8, 2026, 16:25Xiaoying Chen: Teleneurological Ward As A Practical Way to Support High-Quality Stroke Care Beyond Major Centres
-
Apr 8, 2026, 16:24Ney Carter Borges: Endocrine Drivers of Resistant Hypertension – Insights from the MOMENTUM Trial at ACC 26
-
Apr 8, 2026, 16:21Jonathan Gelber: Exploring Papaya Extract as an Option to Elevate Platelet Numbers Before PRP